Furthermore, overexpression of CD36 has been linked to poor prognosis and immunosuppressive tumor microenvironments, positioning CD36 as a compelling therapeutic target with ongoing preclinical exploration using antibodies, inhibitors, and genetic models [16,17]. Here, CD36 is linked to neoplasm.